Merck Looks Ahead To Phase III-Rich Period As Keytruda Winds Down

 
• By Alaric DeArment
  
Merck announced its fourth quarter and full-year 2025 earnings. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business